NEW BRUNSWICK, N.J.,
Nov. 14, 2020 /PRNewswire/
-- Johnson & Johnson (NYSE: JNJ) (the Company) announced
the expansion to the partnership between its Janssen
Pharmaceutical Companies (Janssen) and the Biomedical Advanced
Research and Development Authority (BARDA), which is part of the
Office of the Assistant Secretary for Preparedness and Response
(ASPR) at the U.S. Department of Health and Human Services for the
ongoing development of Janssen's investigational COVID-19 vaccine
candidate.
Under the amendment, Janssen will commit approximately
$604 million and BARDA will commit
approximately $454 million to support
the ongoing Phase 3 ENSEMBLE trial evaluating Janssen's
investigational COVID-19 vaccine candidate as a single-dose in
up to 60,000 volunteers worldwide.
Paul Stoffels, M.D., Vice
Chairman of the Executive Committee and Chief Scientific Officer,
Johnson & Johnson, said, "We greatly value the ongoing
confidence and support of our investigational COVID-19 vaccine
candidate development program. Combined with our own significant
investment, this agreement has enabled our vital research and
development and underscores the importance of public-private
partnerships to tackle the worldwide COVID-19 pandemic."
This project has been funded in whole or in part with Federal
funds from the Office of the Assistant Secretary for
Preparedness and Response, Biomedical Advanced Research and
Development Authority, under OTA No. HHSO100201700018C.
Johnson & Johnson affirmed its commitment to develop and
test its Janssen COVID-19 vaccine candidate in accordance with high
ethical standards and sound scientific principles, as outlined in a
pledge made by nine vaccine manufacturers earlier this
year.
For more information on Johnson & Johnson's multi-pronged
approach to combatting the pandemic, visit:
www.jnj.com/coronavirus.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation
of vibrant lives, thriving communities and forward progress. That's
why for more than 130 years, we have aimed to keep people well at
every age and every stage of life. Today, as the world's largest
and most broadly-based healthcare company, we are committed to
using our reach and size for good. We strive to improve access and
affordability, create healthier communities, and put a healthy
mind, body and environment within reach of everyone, everywhere. We
are blending our heart, science and ingenuity to profoundly change
the trajectory of health for humanity. Learn more at www.jnj.com.
Follow us at @JNJNews.
About the Janssen Pharmaceutical Companies
At Janssen,
we're creating a future where disease is a thing of the past. We're
the Pharmaceutical Companies of Johnson & Johnson, working
tirelessly to make that future a reality for patients everywhere by
fighting sickness with science, improving access with ingenuity,
and healing hopelessness with heart. We focus on areas of medicine
where we can make the biggest difference: Cardiovascular &
Metabolism, Immunology, Infectious Diseases & Vaccines,
Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at
www.janssen.com. Follow us at @JanssenGlobal.
Notice to Investors Concerning Forward-Looking
Statements
This press release contains
"forward-looking statements" as defined in the Private Securities
Litigation Reform Act of 1995 regarding development of a potential
preventive vaccine for COVID-19. The reader is cautioned not to
rely on these forward-looking statements. These statements are
based on current expectations of future events. If underlying
assumptions prove inaccurate or known or unknown risks or
uncertainties materialize, actual results could vary materially
from the expectations and projections of the Janssen Pharmaceutical
Companies, and/or Johnson & Johnson. Risks and uncertainties
include, but are not limited to: challenges and uncertainties
inherent in product research and development, including the
uncertainty of clinical success and of obtaining regulatory
approvals; uncertainty of commercial success; manufacturing
difficulties and delays; competition, including technological
advances, new products and patents attained by competitors;
challenges to patents; product efficacy or safety concerns
resulting in product recalls or regulatory action; changes in
behavior and spending patterns of purchasers of health care
products and services; changes to applicable laws and regulations,
including global health care reforms; and trends toward health care
cost containment. A further list and descriptions of these risks,
uncertainties and other factors can be found in Johnson &
Johnson's Annual Report on Form 10-K for the fiscal year ended
December 29, 2019, including in the
sections captioned "Cautionary Note Regarding Forward-Looking
Statements" and "Item 1A. Risk Factors," and in the company's most
recently filed Quarterly Report on Form 10-Q, and the company's
subsequent filings with the Securities and Exchange Commission.
Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. None of the
Janssen Pharmaceutical Companies nor Johnson & Johnson
undertakes to update any forward-looking statement as a result of
new information or future events or developments.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-and-us-department-of-health--human-services-expand-agreement-to-support-next-phase-of-covid-19-vaccine-candidate-research-and-development-301173112.html
SOURCE Johnson & Johnson